Account
Inquiry
XCE Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This pharmaceutical grade compound is presented as a white lyophilized powder with 99% purity, specifically designed for research applications.
The molecular structure of XCE Tirzepatide features a lysine side chain with PEG modification, which enhances the peptide's water solubility while maintaining its biological activity. As a dual agonist, it demonstrates superior efficacy compared to single receptor agonists in clinical studies for type 2 diabetes and obesity management.
Research indicates XCE Tirzepatide offers multiple metabolic benefits including enhanced insulin secretion, delayed gastric emptying, appetite suppression, and improved glycemic control. Clinical trials have shown significant weight reduction effects comparable to bariatric surgery outcomes.
This compound is particularly valuable for studies investigating: - Glucose metabolism regulation - Appetite control mechanisms - Weight management interventions - Diabetes treatment alternatives - Metabolic syndrome research
XCE Tirzepatide represents a significant advancement in peptide therapeutics, combining the benefits of two incretin hormones in a single molecule. Its unique mechanism of action makes it an important research tool for developing next-generation metabolic disorder treatments.
